Please wait while the formulary information is being retrieved.
CUROSURF (PORACTANT ALFA)
- Respiratory distress syndrome in the newborn
120 mg/1.5 mL intratracheal suspension
- Dosage information is not available
240 mg/3 mL intratracheal suspension
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Bradycardia
- Hypotension
Severe
Moderate
- None
CUROSURF (PORACTANT ALFA)
- Respiratory distress syndrome in the newborn
- Bradycardia
- Hypotension
- None
More Frequent
Severe
Less Severe
- Endotracheal tube blockage
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hypoxia
- Pulmonary hemorrhage
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Poractant
- Severity Level:
2
- Additional Notes: Insufficient data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Poractant Alfa
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory distress syndrome in the newborn | |
| P22.0 | Respiratory distress syndrome of newborn |
| 0-9 | A-Z |
|---|---|
| P22.0 | Respiratory distress syndrome of newborn |
Formulary Reference Tool